干扰素与病毒唑联合治疗慢性丙型肝炎疗效及与干扰素抗体关系的探讨

Study on the relationship between the efficacy of IFN and ribavirin on chronic hepatitis C and the anti-IFN antibodies.

目的 研究干扰素α 2b(interferonα 2b ,IFNα 2b)与病毒唑 (ribavirin)联合治疗慢性丙型肝炎疗效及与IFN抗体的关系。方法 观察组 2 0例采用IFNα 2b 3MU每周 3次皮下注射 +病毒唑l0 5 0mg每天 1次口服 ,连用 2 4周 ;对照组 32例采用IFNα 2b 3MU每周 3次皮下注射 ,连用 2 4周。停药后观察 2 4周比较疗效并检测干扰素抗体。结果 观察组完全应答率为 5 0 %,明显高于对照组 18 7%;复发率为 2 5 %,低于对照组 5 6 3%。无反应率均为 2 5 %。且复发与干扰素抗体尤其是中和抗体有关。结论 干扰素与病毒唑联合治疗慢性丙型肝炎的疗效优于单独干扰素治疗组 ,复发与干扰素抗体尤其是中和抗体有关。

Objective In order to study the relationship between the efficacy of IFN and ribavirin in treating the patients with chronic hepatitis C and the anti-IFN antibodies.Methods 20 patients received 3MU rIFN α-2b three times a week and ribavirim 1?050mg once a day for 24 weeks;32 patients were treated with 3MU rIFN α-2b and without ribavin.These patients were all followed up 24weeks after stopping treatment,meanwhile the anti-IFN antibodies were detected.Results In first group,50% of the patients had complete response,which was higher obviously than 18.7% in the second group;25%relapse developed in the first group,which was lower than 56.3% in the second group.25% of the patients had no response in each groups.The relapse was related to the anti-IFN antibodies,especially neutralizing antibodies.Conclusion The efficacy of combined treatment with IFNα-2b and ribavirin is superior to the treatment with only rIFNα-2b.The relapse is related to anti-IFN antibodies,especially neutralizing antibodies.